Evommune, Inc.

NYSE:EVMN Stock Report

Market Cap: US$383.2m

Evommune Management

Management criteria checks 2/4

Evommune's CEO is Luis Pena, appointed in Apr 2020, has a tenure of 6.42 years. total yearly compensation is $11.02M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth $5.16M. The average tenure of the management team and the board of directors is 4.3 years and 6 years respectively.

Key information

Luis Pena

Chief executive officer

US$11.0m

Total compensation

CEO salary percentage5.34%
CEO tenure6.4yrs
CEO ownership1.3%
Management average tenure4.3yrs
Board average tenure6yrs

Recent management updates

Recent updates

Analysis Article • Sep 03

We're Hopeful That Evommune (NYSE:EVMN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 11

Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge

Summary Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic dermatitis. EVO301's multi-pathway IL-18 inhibition offers broad potential, but mechanistic complexity and early-stage risks warrant caution. I maintain a hold rating due to the early stage, possible safety/efficacy uncertainties, and the sharp recent stock appreciation. Upcoming Phase 2b with subcutaneous dosing is a key catalyst; a cash runway of 9–10 months supports near-term development. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Luis Pena's remuneration changed compared to Evommune's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$95m

Mar 31 2026n/an/a

-US$76m

Dec 31 2025US$11mUS$588k

-US$69m

Sep 30 2025n/an/a

-US$63m

Jun 30 2025n/an/a

-US$66m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$7mUS$546k

-US$68m

Compensation vs Market: Luis's total compensation ($USD11.02M) is above average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Luis's compensation has increased whilst the company is unprofitable.

CEO

Luis Pena (63 yo)

6.4yrs
Tenure
US$11,022,670
Compensation

Mr. Luis C. Pena has been Founder, President, Chief Executive Officer and Director at Evommune Inc. since April 2020. He Co-founded Dermira Inc. in August 2010 and had been its Chief Development Officer si...

Leadership Team

NamePositionTenureCompensationOwnership
Luis Pena
Founder6.4yrsUS$11.02m1.35%
$ 5.2m
Kyle Carver
Chief Financial Officer4.5yrsUS$4.40m0.016%
$ 61.9k
Gregory Moss
Chief Business & Legal Officer4.3yrsUS$4.60m0.022%
$ 86.2k
Eugene Bauer
Co-Founderno datano data0.72%
$ 2.8m
Jeegar Patel
Chief Scientific Officer3.9yrsno data0.016%
$ 63.0k
Janice Drew
Chief of Development Operationsless than a yearno data0.11%
$ 430.3k
Lou Sehl
Senior Vice President of Technical Operations4.3yrsno datano data
Daniel Burge
Senior Vice President of Clinical Developmentno datano datano data
J. Jackson
Senior Vice President of Clinical Developmentless than a yearno datano data
4.3yrs
Average Tenure
63yo
Average Age

Experienced Management: EVMN's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Luis Pena
Founder6.4yrsUS$11.02m1.35%
$ 5.2m
Eugene Bauer
Co-Founder6.4yrsno data0.72%
$ 2.8m
Arthur Kirsch
Independent Directorless than a yearUS$451.24k0.028%
$ 105.6k
Benjamin McGraw
Independent Chairman of the Board5.9yrsUS$490.83k0%
$ 0
Robert Hopfner
Independent Director6.2yrsno data0.011%
$ 42.5k
David Cohen
Independent Director6.3yrsUS$484.58k0.049%
$ 186.0k
Felice Verduyn-Van Weegen
Independent Director5yrsno datano data
Derek DiRocco
Independent Director1.9yrsno datano data
6.0yrs
Average Tenure
62yo
Average Age

Experienced Board: EVMN's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 15:12
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evommune, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prakhar AgrawalCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI
Mitchell KapoorH.C. Wainwright & Co.